WE ARE SWISS GREEN ROSE

The Medical
Cannabis Holding

INVESTORS WANTED

Initial Public Offering
Pre-IPO Shares

WE BELIEVE IN VALUES

Value-Based Leadership
                     & Management

WE ARE SUSTAINABLE

For A Better Tomorrow

About us

Swiss Green Rose PLC is a Stock Exchange-listed, London-based holding company that owns various subsidiaries in Germany and Greece to produce medical-grade cannabis, as well as to develop and commercialize cannabis-based medicines in Europe.

The basis for optimal patient care is pharmaceutical-grade cannabis. With a production area currently under construction covering a total of 1,000,000m² in Orestiada Greece (430,000m² in stock, another 600,000m² are currently being processed) we are laying the foundation to be the market leader in the future. With our existing area, we are already becoming one of the largest plantations in the world. We have a strong team of specialists who have a lot of scientific know-how and who will take care of and guarantee the cultivation of cannabis from the offshoot in the laboratory to the harvest.

The plan is to produce high quality cannabis in the form of dried flowers and THC oil – ISO certified and licensed by the Greek government. In cooperation with our laboratory, we will produce narcotic cannabis extracts for the extemporaneous prescription for pharmacies.

Our Details

– Address: No 1 Royal Exchange, London, EC3V 3DG, United Kingdom
– Email: info@swissgreenrose.com
– Telephone: +44 20 4525 4165
– Company No.: 12410636, founded 17.01.2020
– ISIN Number: GB00BP37YF56

News & Stories

Our Directors

Domenico F. Kaleyta
Domenico F. Kaleyta

Director

Martin Fuchs

Martin Fuchs

Director

Our Advisors

Company Secretary
Legal Advisor

 

Simon Charles

Marriott Harrison LLP

 

Accountants & Auditor

 

Sanjay Parmar

Jeffreys Henry LLP

 

Registrar

 

Hardeep Tamana

Avenir Registrars Ltd.

Project Development

Our Management Team

Dimitris Flokos

Dimitris Flokos

COO Greece

Athanasios Pechlivanidis

Athanasios Pechlivanidis

CEO Production Facility

   Mounir Saab

Mounir Saab

Finance & Head of Sales Middle East & Africa

Radoslav Mirchev Ognyanov

Radoslav Mirchev Ognyanov

Head of Security Services

MEDIZINISCHE CANNABIS

For thousands of years, cannabis has been used as a medicine for the treatment of various diseases. Already in ancient Greece, the miracle plant was used as a remedy to alleviate clinical symptoms. Cannabis was first discovered in 1400 BC in China , where the active ingredient was used to treat patients in remote areas.

The cannabis plant grows in 3 flowering varieties. Indica, Sativa and Hybrid. In medicine, people mainly use Sativa and Indica for the specific treatment of the medical problems. To date, over 600 compounds such as amino acids, terpenes and proteins have been detected in the cannabis plant. It contains over 100 different phytocannabinoids, of which the most therapeutically relevant are the active ingredients cannabidiol (CBD) and tetrahydrocannabinol (THC).

It is only through decarboxylation, which is achieved by heating the plants, that the active molecules THC and CBD are released. Once the active ingredient THC enters the patient’s body, it docks with the patient’s receptors and affects certain processes in the central nervous system and immune system.

 

Cannabis affects the endocannabinoid system in the body. Parts of this nervous system are CB1 and CB2 receptors. Physiological processes such as , appetite, pain perception, inflammation, sleep and mood are regulated in part by the endocannabinoid system. Clinical studies with single cannabinoids or whole plant preparations (smoked cannabis, cannabis extract) have often been inspired by positive anecdotal experiences of patients employing crude can-nabis products.

Depending on the country, THC products may be prescribed under strict conditions in the form of a doctor’s prescription. See Narcotics Law. Only when alternative medications do not help a patient are doctors allowed to prescribe THC medications. Medical THC products are very price-intensive, which can repeatedly lead to conflicts with health insurance companies.

Production Process

Highly automated from plant growing over processing, trimming, dehumidifying to the oil extraction and finally medical products.

übersicht

Our Production Areas (Projects)

Athens 78km North

THC Oil Production per Year in kg

Total Area in m²

Orestiada

THC Oil Production per Year in kg

Total Area in m²

Contact Us

Swiss Green Rose PLC

No 1 Royal Exchange
London EC3V 3DG

Contacts

+44 20 4525 4165
info@swissgreenrose.com